Acumen Pharmaceuticals Files 8-K on Security Holder Vote
Ticker: ABOS · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1576885
| Field | Detail |
|---|---|
| Company | Acumen Pharmaceuticals, INC. (ABOS) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Acumen Pharma held a shareholder vote on June 4th, details to follow.
AI Summary
Acumen Pharmaceuticals, Inc. filed an 8-K on June 5, 2024, reporting on matters submitted to a vote of security holders on June 4, 2024. The filing does not detail the specific matters voted upon but indicates a formal submission occurred.
Why It Matters
This filing signals that Acumen Pharmaceuticals held a vote among its security holders, which could pertain to significant corporate actions or governance changes.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Acumen Pharmaceuticals, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- June 5, 2024 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Acumen Pharmaceuticals' security holders on June 4, 2024?
The filing does not specify the exact matters voted upon, only that matters were submitted for a vote.
What is the primary purpose of this 8-K filing for Acumen Pharmaceuticals?
The primary purpose is to report that matters were submitted to a vote of security holders on June 4, 2024.
When was this 8-K filing submitted to the SEC?
The filing was submitted on June 5, 2024.
What is Acumen Pharmaceuticals' state of incorporation and fiscal year end?
Acumen Pharmaceuticals is incorporated in Delaware and its fiscal year ends on December 31.
What is the principal executive office address for Acumen Pharmaceuticals?
The principal executive office is located at 427 Park St., Charlottesville, Virginia 22902.
Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-05 16:36:13
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ABOS The Nasdaq Global Select
Filing Documents
- abos-20240604.htm (8-K) — 31KB
- 0001576885-24-000067.txt ( ) — 155KB
- abos-20240604.xsd (EX-101.SCH) — 2KB
- abos-20240604_lab.xml (EX-101.LAB) — 22KB
- abos-20240604_pre.xml (EX-101.PRE) — 13KB
- abos-20240604_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 4, 2024, Acumen Pharmaceuticals, Inc. (the " Company ") held its 2024 annual meeting of stockholders (the " Annual Meeting "). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2024. Of the 60,079,778 shares outstanding as of the record date, 52,381,009 shares, or approximately 87%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. Proposal No. 1: The stockholders elected two nominees to serve as Class III directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes Daniel O'Connell 40,490,834 48,338 11,841,837 Nathan Fountain, M.D. 34,164,444 6,371,549 11,845,016 Proposal No. 2: The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 52,367,645 7,093 6,271
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acumen Pharmaceuticals, Inc. Dated: June 5, 2024 By: /s/ Derek Meisner Derek Meisner Chief Legal Officer